Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study

Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Journal of Alzheimer’s Disease, 27 February 2016

BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia…

Cannabinoids in late‐onset Alzheimer’s disease

Authors: AIA Ahmed, MA van der Marck, GAH van den Elsen, MGM Olde Rikkert
Clinical Pharmacology & Therapeutics, 8 March 2015

Given the lack of effective treatments for late-onset Alzheimer’s disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing…

The potential therapeutic effects of THC on Alzheimer’s disease

Authors: Chuanhai Cao, Yaqiong Li, Hui Liu, Ge Bai, Jonathan Mayl, Xiaoyang Lin, Kyle Sutherland, Neel Nabar, Jianfeng Cai
Journal of Alzheimer’s Disease, 16 September 2014

The purpose of this study was to investigate the potential therapeutic qualities of Δ9-tetrahydrocannabinol (THC) with respect to slowing or halting the hallmark characteristics of Alzheimer’s disease. N2a-variant amyloid-β protein precursor (AβPP) cells were incubated with TH…

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic.

Authors: Ester Aso, Isidre Ferrer
Frontiers in Pharmacology, 5 March 2014

The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabino…

Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia

Authors: Sebastian Walther, Richard Mahlberg, Uta Eichmann, Dieter Kunz
Psychopharmacology, May 2006

Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects. The aim of the study was to measure the effect of the cannabinoid dronabinol…

A molecular link between the active component of marijuana and Alzheimer’s disease pathology.

Authors: Lisa M. Eubanks, Claude J. Rogers, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, Kim D. Janda
Molecular Pharmaceutics, 2006

Alzheimer’s disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer’s disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease p…